University of Arkansas for Medical Sciences, 4301 West Markham, Slot #781, Little Rock, AR 72205, USA.
University of California, San Francisco, Hematology Oncology, 1600 Divisadero Street, Room A641, Box 1699, San Francisco, CA 94143, USA.
Contemp Clin Trials. 2022 Feb;113:106679. doi: 10.1016/j.cct.2022.106679. Epub 2022 Jan 10.
It is well established that persons living with HIV (PLWH) have highly elevated rates of anal HSIL and anal cancer compared with those who are not living with HIV. The 5-year risk of anal cancer following anal HSIL has been reported to be as high as 14.1% among PLWH compared with 3.2% among those who are not living with HIV. To address these concerns, the AIDS Malignancy Consortium completed a large-scale, randomized trial to compare strategies for the prevention of anal cancer among PLWH with anal HSIL. The objective of the study was to determine whether treating anal HSIL was effective in reducing the incidence of anal cancer in PLWH compared with active monitoring. This paper describes the design of the ANal Cancer/HSIL Outcomes Research Study (ANCHOR) with respect to estimating the anal cancer event rate in this high risk population.
已经证实，与未感染 HIV 的人群相比，HIV 感染者（PLWH）肛门高度不典型增生（HSIL）和肛门癌的发病率极高。据报道，PLWH 发生肛门癌的 5 年风险高达 14.1%，而未感染 HIV 的人群为 3.2%。为了解决这些问题，艾滋病恶性肿瘤联合会（AIDS Malignancy Consortium）完成了一项大规模、随机试验，以比较针对 HIV 感染者肛门 HSIL 的预防策略。该研究的目的是确定与主动监测相比，治疗肛门 HSIL 是否能有效降低 PLWH 肛门癌的发病率。本文介绍了 ANal Cancer/HSIL Outcomes Research Study（ANCHOR）的设计，旨在估计该高危人群中肛门癌的发生率。
